NCT06268145Recruiting

ECC5004 RBA FE Study in Healthy Participants

Name: Clinical Trial NCT06268145
Creator: Eccogene
Keywords: Type 2 Diabetes Mellitus, ECC5004, Phase 1, drug, clinical trial, United States of America

An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Tablet Formulation (F2) of ECC5004 and Food Effects on F1 and F2 of ECC5004 in Healthy Participants

EccogenePhase 1ClinicalTrials.govdrug

Verified

Study focus

Disease/Condition: Type 2 Diabetes Mellitus
Drug/Device/Intervention: ECC5004
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Eccogene
Location: Anaheim, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: Feb 06, 2024
End date: Mar 30, 2024
Enrollment: 14 participants

Primary outcome

ECC5004 PK parameters: AUC0-tlast,ECC5004 PK parameters: AUC0-inf,ECC5004 PK parameters: Cmax,ECC5004 PK parameters: tmax

Summary

This study is a Phase 1, open-label, randomized, single dose, fixed sequence, crossover study designed to compare the relative bioavailability of 50 mg ECC5004 current tablet formulation (F1) and 50 mg ECC5004 new tablet formulation (F2) under fasted and fed conditions in healthy participants

ICD-10 classifications

Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06268145
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06268145 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eccogene and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 14 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.